Upstream Bio, Inc. Signs Material Sales Agreement for Common Stock Offering

Key Points from the SEC Filing

• Date of Event: March 26, 2026
• Company: Upstream Bio, Inc. (Ticker: UPB)
• Exchange: The Nasdaq Global Select Market
• Form Filed: 8-K (Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934)
• Material Agreement: Entry into a Sales Agreement with Leerink Partners LLC

Details of the Material Definitive Agreement

On March 26, 2026, Upstream Bio, Inc. announced that it has entered into a Sales Agreement with Leerink Partners LLC, acting as sales agent. This agreement enables the company to offer and sell shares of its common stock (\$0.001 par value per share) from time to time via an “at-the-market” (ATM) offering program. The common stock is listed on The Nasdaq Global Select Market under the symbol “UPB”.

The ATM Sales Agreement allows Upstream Bio to raise capital by selling shares directly into the market at prevailing prices, providing flexibility to access funding as needed. The company has not disclosed the maximum number of shares or the total value of the offering in the 8-K, but the actual sales will be governed by specific Placement Notices delivered to Leerink Partners. Each notice will specify parameters such as the maximum number of shares to be sold, the time period for sales, and minimum prices.

Potential Shareholder Impact

• Share Dilution: The ATM offering could result in dilution of existing shareholders as new shares may be issued and sold in the market. The company confirms that all shares sold will be validly issued, fully paid, and nonassessable.
• Use of Proceeds: The proceeds from the offering are expected to be used for general corporate purposes, including but not limited to working capital, capital expenditures, and potential acquisitions. The specifics of use will be outlined in future filings and communications.
• Price Sensitivity: The announcement of an ATM program can be price sensitive. If the company sells a substantial number of shares, it could put downward pressure on the share price due to dilution and increased supply in the market.
• Regulatory Compliance: Upstream Bio affirms compliance with all relevant SEC regulations, including maintaining effective disclosure controls, internal controls over financial reporting, and timely filings with the Commission. The company also confirms it is an “emerging growth company” under the Securities Act, which may allow it to take advantage of certain reduced reporting obligations.
• No Stop Order: The company has not received any notice from the SEC objecting to the use of the shelf registration statement form and confirms no stop order is currently preventing or suspending the use of the registration statement.
• Legal Opinion: Goodwin Procter LLP provided a legal opinion confirming that shares issued under the agreement will be validly issued, fully paid, and nonassessable.
• Listing Commitment: The company will use commercially reasonable efforts to ensure all shares sold under the ATM will remain listed on Nasdaq, and has engaged and will maintain a transfer agent for its common stock.
• Indemnification & Expenses: The company will indemnify the agent against certain taxes and will bear all expenses related to the offering, including preparation, filing, and legal costs.
• Market Activities: The company commits not to engage in market manipulation or stabilization activities in connection with the ATM offering, except as allowed under Rule 10b-18 for share buybacks.

Additional Information for Investors

• The ATM program provides Upstream Bio with a flexible tool to raise capital as needed, which can support ongoing operations, R&D, and potential growth initiatives.
• Investors should monitor future Placement Notices and prospectus supplements for details on actual shares sold, timing, and price parameters. These details will be disclosed in subsequent filings.
• No other material adverse changes or events have been reported as of the date of the filing.
• The company confirms it does not possess any material non-public information that would impact the share value or require additional disclosure at this time.

Signatories

• Upstream Bio, Inc.: E. Rand Sutherland, Chief Executive Officer; Michael Paul Gray, Chief Financial and Operating Officer
• Leerink Partners LLC: Peter Fry, Head of Alt Equities

Conclusion

The entry into the ATM Sales Agreement is a significant development for Upstream Bio, Inc., as it provides the company with a mechanism to raise capital efficiently and flexibly. Investors should be aware of the potential for share dilution and monitor future filings for details on the execution of the offering. The legal and regulatory compliance measures outlined in the agreement also provide reassurance regarding the validity and proper handling of the offering.

Disclaimer: This article is based on information from Upstream Bio, Inc.’s SEC filings as of March 26, 2026. It is for informational purposes only and does not constitute investment advice. Investors should review all relevant filings and consult their financial advisors before making investment decisions. The author does not guarantee the accuracy or completeness of the information and accepts no liability for actions taken based on this report.

View Upstream Bio, Inc. Historical chart here